Back
58
37
Day Range
$267.16
$276.08
52-Week Range
$234.60
$606.36
Volume
8,103,300
50D / 200D Avg
$298.51
/
$314.23
Prev Close
$272.28
Quick Summary
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (631 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 20.4 | 0.2 |
| P/B | 2.6 | 3.0 |
| ROE % | 12.9 | 3.6 |
| Net Margin % | 2.7 | 3.8 |
| Rev Growth 5Y % | 11.7 | 9.9 |
| D/E | 0.8 | 0.2 |
Analyst Price Target
Hold
$385.38
+42.4%
Low: $327.00
High: $444.00
Forward P/E
15.15
Forward EPS
$17.85
EPS Growth (est.)
+0.0%
Est. Revenue
441.45B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$32.46
$31.77 – $34.06
|
539.73B | 4 |
| FY2029 |
$28.68
$28.07 – $30.10
|
509.79B | 4 |
| FY2028 |
$23.78
$22.33 – $26.27
|
481.53B | 10 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-01-27 | $2.10 | $2.11 | +0.5% |
| 2025-10-28 | $2.80 | $2.92 | +4.3% |
| 2025-07-29 | $4.45 | $4.08 | -8.3% |
| 2025-04-17 | $7.29 | $7.20 | -1.2% |
| 2025-01-16 | $6.74 | $6.81 | +1.0% |
| 2024-10-15 | $7.00 | $7.15 | +2.1% |
| 2024-07-16 | $6.65 | $6.80 | +2.3% |
| 2024-04-16 | $6.61 | $6.91 | +4.5% |
Insider Trading Activity
18 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 |
Baker Charles D.
Director
|
grant | 14 | — | — |
| Feb 20, 2026 |
ROOS THOMAS E
Chief Accounting Officer
|
other | 326 | $290.00 | $94,540.00 |
| Jan 2, 2026 |
Gottlieb Scott
Director
|
grant | 125 | — | — |
| Jan 2, 2026 |
Baker Charles D.
Director
|
grant | 279 | — | — |
| Dec 16, 2025 |
MCNABB FREDERICK WILLIAM III
Director
|
grant | 53 | — | — |
| Oct 1, 2025 |
FLYNN TIMOTHY PATRICK
Director
|
grant | 272 | — | — |
| Sep 23, 2025 |
FLYNN TIMOTHY PATRICK
Director
|
grant | 61 | — | — |
| Sep 23, 2025 |
MCNABB FREDERICK WILLIAM III
Director
|
grant | 49 | — | — |
| Sep 11, 2025 |
Baker Charles D.
Director
|
sell | 27 | $356.05 | $9,613.35 |
| Jul 1, 2025 |
MONTGOMERY RICE VALERIE MD
Director
|
grant | 288 | — | — |
| Jul 1, 2025 |
Gil Kristen
Director
|
grant | 173 | — | — |
| Jun 24, 2025 |
Noseworthy John H
Director
|
grant | 42 | — | — |
| Jun 24, 2025 |
Noel Timothy John
Chief Executive Officer, UHC
|
grant | 48 | — | — |
| Jun 6, 2025 |
McSweeney Erin
EVP & Chief People Officer
|
other | 130 | $303.22 | $39,418.60 |
| Jun 3, 2025 |
Zaetta Christopher R
EVP & Chief Legal Officer
|
other | 115 | $301.22 | $34,640.30 |
| May 14, 2025 |
FLYNN TIMOTHY PATRICK
Director
|
buy | 1,533 | $320.80 | $491,786.40 |
| Apr 1, 2025 |
Gil Kristen
Director
|
grant | 108 | — | — |
| Apr 1, 2025 |
HOOPER MICHELE J
Director
|
grant | 108 | — | — |
Dividend History
7 yr streakYield
0.03%
Payout Ratio
0.66%
Growth (3Y)
10.90%
Growth (5Y)
12.57%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Mar 09, 2026 | Mar 17, 2026 | $2.21 | 3.10% |
| Dec 08, 2025 | Dec 16, 2025 | $2.21 | 2.70% |
| Sep 15, 2025 | Sep 23, 2025 | $2.21 | 2.48% |
| Jun 16, 2025 | Jun 24, 2025 | $2.21 | 2.77% |
| Mar 10, 2025 | Mar 18, 2025 | $2.10 | 1.75% |
| Dec 09, 2024 | Dec 17, 2024 | $2.10 | 1.46% |
| Sep 16, 2024 | Sep 24, 2024 | $2.10 | 1.35% |
| Jun 17, 2024 | Jun 25, 2024 | $2.10 | 1.58% |
| Mar 08, 2024 | Mar 19, 2024 | $1.88 | 1.58% |
| Dec 01, 2023 | Dec 12, 2023 | $1.88 | 1.33% |
| Sep 08, 2023 | Sep 19, 2023 | $1.88 | 1.47% |
| Jun 15, 2023 | Jun 27, 2023 | $1.88 | 1.47% |
| Mar 10, 2023 | Mar 21, 2023 | $1.65 | 1.43% |
| Dec 02, 2022 | Dec 13, 2022 | $1.65 | 1.19% |
| Sep 09, 2022 | Sep 20, 2022 | $1.65 | 1.18% |
| Jun 16, 2022 | Jun 28, 2022 | $1.65 | 1.32% |
| Mar 11, 2022 | Mar 22, 2022 | $1.45 | 1.20% |
| Dec 03, 2021 | Dec 14, 2021 | $1.45 | 1.25% |
| Sep 10, 2021 | Sep 21, 2021 | $1.45 | 1.34% |
| Jun 18, 2021 | Jun 29, 2021 | $1.45 | 1.34% |
Key Takeaways
Revenue grew 11.69% annually over 5 years — strong growth
Earnings declined -16.31% over the past year
ROE of 12.91% — decent returns on equity
Generating 16.08B in free cash flow
Cash machine — converts 133.34% of earnings into free cash flow
Capital efficient — spends only 0.81% of revenue on capex
Growth
Revenue Growth (5Y)
11.69%
Revenue (1Y)11.81%
Earnings (1Y)-16.31%
FCF Growth (3Y)-20.88%
Quality
Return on Equity
12.91%
ROIC8.25%
Net Margin2.69%
Op. Margin4.24%
Safety
Debt / Equity
0.83
Current Ratio0.79
Interest Coverage4.74
Valuation
P/E Ratio
20.37
Forward P/E15.15
P/B Ratio2.61
EV/EBITDA15.80
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11.81% | Revenue Growth (3Y) | 9.74% |
| Earnings Growth (1Y) | -16.31% | Earnings Growth (3Y) | -26.61% |
| Revenue Growth (5Y) | 11.69% | Earnings Growth (5Y) | -8.61% |
| Profitability | |||
| Revenue (TTM) | 447.57B | Net Income (TTM) | 12.06B |
| ROE | 12.91% | ROA | 3.89% |
| Gross Margin | 18.53% | Operating Margin | 4.24% |
| Net Margin | 2.69% | Free Cash Flow (TTM) | 16.08B |
| ROIC | 8.25% | FCF Growth (3Y) | -20.88% |
| Safety | |||
| Debt / Equity | 0.83 | Current Ratio | 0.79 |
| Interest Coverage | 4.74 | ||
| Dividends | |||
| Dividend Yield | 0.03% | Payout Ratio | 0.66% |
| Dividend Growth (3Y) | 10.90% | Dividend Growth (5Y) | 12.57% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 20.37 | Forward P/E | 15.15 |
| P/B Ratio | 2.61 | P/S Ratio | 0.55 |
| PEG Ratio | -1.62 | Forward PEG | N/A |
| EV/EBITDA | 15.80 | Fwd EV/EBITDA | 8.24 |
| Forward P/S | 0.56 | Fwd Earnings Yield | 6.60% |
| FCF Yield | 6.55% | ||
| Market Cap | 245.57B | Enterprise Value | 299.60B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 447.57B | 400.28B | 371.62B | 324.16B | 287.60B |
| Net Income | 12.06B | 14.41B | 22.38B | 20.12B | 17.29B |
| EPS (Diluted) | 13.23 | 15.51 | 23.86 | 21.18 | 18.08 |
| Gross Profit | 82.92B | 89.40B | 90.96B | 79.62B | 69.65B |
| Operating Income | 18.96B | 32.29B | 32.36B | 28.44B | 23.97B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 309.58B | 298.28B | 273.72B | 245.71B | 212.21B |
| Total Liabilities | 207.88B | 195.69B | 174.80B | 159.36B | 135.73B |
| Shareholders' Equity | 94.11B | 92.66B | 88.76B | 77.77B | 71.76B |
| Total Debt | 78.39B | 76.90B | 67.44B | 57.62B | 46.00B |
| Cash & Equivalents | 24.37B | 25.31B | 25.43B | 23.37B | 21.38B |
| Current Assets | 90.58B | 85.78B | 78.44B | 69.07B | 61.76B |
| Current Liabilities | 114.90B | 103.77B | 99.05B | 89.24B | 78.29B |
Strategy Scores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#250 of 1049
#284 of 619
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026
Entered
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026